BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
1. BNTX expects lower earnings at 25 cents per share for Q4. 2. Quarterly revenue projected at $1.15 billion, down from $1.48 billion. 3. FDA put a clinical hold on BNT165e malaria vaccine trial. 4. BNTX shares fell 3.4% to $110.83 this week. 5. Analysts have mixed ratings with price targets ranging significantly.